Cargando…

Genetic biomarkers for PD-1/PD-L1 blockade therapy

Detalles Bibliográficos
Autores principales:	Kataoka, Keisuke, Ogawa, Seishi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5235916/ https://www.ncbi.nlm.nih.gov/pubmed/28105452 http://dx.doi.org/10.18632/oncoscience.328

Ejemplares similares

Does the gut microbiota play a key role in PD-1/PD-L1 blockade therapy?
por: Watanabe, Satoshi, et al.
Publicado: (2020)

PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade
por: Hirsch, Laure, et al.
Publicado: (2018)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea, Miruna, et al.
Publicado: (2021)

Drug response to PD-1/PD-L1 blockade: based on biomarkers
por: Chen, Qi, et al.
Publicado: (2018)

Is PD-1 blockade a potential therapy for HBV?
por: Féray, Cyrille, et al.
Publicado: (2019)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Oncolytic virus and PD-1/PD-L1 blockade combination therapy
por: Chen, Chun-Yu, et al.
Publicado: (2018)

Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas
por: Katsuya, Hiroo, et al.
Publicado: (2023)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
por: Wu, Mengling, et al.
Publicado: (2022)

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
por: Ma, Weijie, et al.
Publicado: (2016)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

DNA Methylation Biomarkers Predict Objective Responses to PD-1/PD-L1 Inhibition Blockade
por: Xue, Gang, et al.
Publicado: (2019)

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
por: Ren, Daixi, et al.
Publicado: (2020)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
por: Jing, Wang, et al.
Publicado: (2016)

Understanding the role of PD-L1/PD1 pathway blockade and autophagy in cancer therapy
por: Robainas, Marianela, et al.
Publicado: (2017)

Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy
por: Razaghi, Ali, et al.
Publicado: (2023)

PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer
por: Bocanegra, Ana, et al.
Publicado: (2019)

Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor
por: Grossman, Joseph E., et al.
Publicado: (2021)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
por: Zhao, Xuan, et al.
Publicado: (2022)

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
por: Hamanishi, Junzo, et al.
Publicado: (2016)

Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
por: Ren, Daixi, et al.
Publicado: (2020)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer
Publicado: (2021)

Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
por: Zhao, Bin, et al.
Publicado: (2020)

Biomarkers of response to PD-1 pathway blockade
por: Li, Hanxiao, et al.
Publicado: (2022)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer(1)
Publicado: (2020)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer(1)
por: Tu, Megan M., et al.
Publicado: (2019)

Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
por: Gong, Jun, et al.
Publicado: (2018)

PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
por: Jia, Long, et al.
Publicado: (2018)

PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
por: Šmahel, Michal
Publicado: (2017)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Lee, Hyun Tae, et al.
Publicado: (2017)

Role of the PD-1 and PD-L1 axis in COVID-19
por: R Bonam, Srinivasa, et al.
Publicado: (2022)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
por: Jiang, Youhai, et al.
Publicado: (2020)

Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
por: Zhuang, Yuan, et al.
Publicado: (2020)

Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade
por: Tian, Tian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b8qo045n0osl5m8kdovgj7avls